You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
The company offers a blood test that detects human papillomavirus-related cancer by measuring tumor tissue-modified viral DNA using droplet digital PCR.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.
The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.
The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.
The molecular test developed in collaboration with Self-screen identifies HPV 16 and 18 and concurrently detects the other 13 common high-risk types of HPV infection.
The peer-reviewed study assessed sensitivity rates of HPV testing alone, Pap testing alone, and cotesting with both HPV and Pap tests.
Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.